急性髓系白血病中表观遗传定向疗法的临床进展
Clinical developments in epigenetic-directed therapies in acute myeloid leukemia.
作者信息
Pan Darren, Rampal Raajit, Mascarenhas John
机构信息
Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY.
Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY; and.
出版信息
Blood Adv. 2020 Mar 10;4(5):970-982. doi: 10.1182/bloodadvances.2019001245.
Abstract
Acute myeloid leukemia (AML) is a highly heterogeneous disease arising from acquired genetic and epigenetic aberrations which stifle normal development and differentiation of hematopoietic precursors. Despite the complex and varied biological underpinnings, induction therapy for AML has remained fairly uniform over 4 decades and outcomes remain poor for most patients. Recently, enhanced understanding of the leukemic epigenome has resulted in the translational investigation of a number of epigenetic modifying agents currently in various stages of clinical development. These novel therapies are based on mechanistic rationale and offer the potential to improve AML patient outcomes. In light of many recent advances in this field, we provide an updated, clinically oriented review of the evolving landscape of epigenetic modifying agents for the treatment of AML.
摘要
急性髓系白血病（AML）是一种高度异质性疾病，由获得性遗传和表观遗传畸变引起，这些畸变会抑制造血前体细胞的正常发育和分化。尽管其生物学基础复杂多样，但40多年来AML的诱导治疗一直相当统一，大多数患者的治疗效果仍然很差。最近，对白血病表观基因组的深入了解促使人们对目前处于临床开发不同阶段的多种表观遗传修饰剂进行转化研究。这些新疗法基于作用机制原理，有望改善AML患者的治疗效果。鉴于该领域最近的许多进展，我们提供了一篇最新的、以临床为导向的综述，介绍用于治疗AML的表观遗传修饰剂的不断演变的情况。
相似文献
1
Clinical developments in epigenetic-directed therapies in acute myeloid leukemia.急性髓系白血病中表观遗传定向疗法的临床进展
Blood Adv. 2020 Mar 10;4(5):970-982. doi: 10.1182/bloodadvances.2019001245.
2
The evolution of epigenetic therapy in myelodysplastic syndromes and acute myeloid leukemia.表观遗传学治疗在骨髓增生异常综合征和急性髓系白血病中的进展。
Semin Hematol. 2021 Jan;58(1):56-65. doi: 10.1053/j.seminhematol.2020.12.003. Epub 2020 Dec 28.
3
Epigenetic alterations in acute myeloid leukemias.急性髓系白血病中的表观遗传改变。
FEBS J. 2015 May;282(9):1786-800. doi: 10.1111/febs.13142. Epub 2014 Nov 24.
4
Recent advances in the understanding and treatment of acute myeloid leukemia.急性髓系白血病在理解和治疗方面的最新进展。
F1000Res. 2018 Aug 6;7. doi: 10.12688/f1000research.14116.1. eCollection 2018.
5
Epigenetic alterations in AML: Deregulated functions leading to new therapeutic options.AML 中的表观遗传学改变：功能失调导致新的治疗选择。
Int Rev Cell Mol Biol. 2024;387:27-75. doi: 10.1016/bs.ircmb.2024.06.003. Epub 2024 Jul 9.
6
Genetic and epigenetic determinants of AML pathogenesis.AML 发病机制的遗传和表观遗传决定因素。
Semin Hematol. 2019 Apr;56(2):84-89. doi: 10.1053/j.seminhematol.2018.08.001. Epub 2018 Aug 22.
7
Precision therapy for acute myeloid leukemia.精准治疗急性髓系白血病。
J Hematol Oncol. 2018 Jan 5;11(1):3. doi: 10.1186/s13045-017-0543-7.
8
Identifying high-risk adult AML patients: epigenetic and genetic risk factors and their implications for therapy.识别高危成年急性髓系白血病患者：表观遗传和遗传风险因素及其对治疗的影响。
Expert Rev Hematol. 2016;9(4):351-60. doi: 10.1586/17474086.2016.1141673. Epub 2016 Feb 12.
9
New treatment for acute myelogenous leukemia.急性髓系白血病的新疗法。
Expert Opin Pharmacother. 2015 Jan;16(1):95-106. doi: 10.1517/14656566.2015.981527. Epub 2014 Dec 5.
10
Toward Individualized Therapy in Acute Myeloid Leukemia: A Contemporary Review.迈向急性髓系白血病的个体化治疗：当代综述。
JAMA Oncol. 2015 Sep;1(6):820-8. doi: 10.1001/jamaoncol.2015.0617.
引用本文的文献
1
Synergistic cytotoxicity of decitabine and YM155 in leukemia cells through upregulation of SLC35F2 and suppression of MCL1 and survivin expression.地西他滨与 YM155 联合作用通过上调 SLC35F2 表达和抑制 MCL1、survivin 表达诱导白血病细胞发生协同细胞毒作用。
Apoptosis. 2024 Apr;29(3-4):503-520. doi: 10.1007/s10495-023-01918-1. Epub 2023 Dec 8.
2
Therapeutic targeting of leukemia stem cells in acute myeloid leukemia.急性髓系白血病中白血病干细胞的治疗靶点
Front Oncol. 2023 Aug 3;13:1204895. doi: 10.3389/fonc.2023.1204895. eCollection 2023.
3
Therapeutic Applications of Azanucleoside Analogs as DNA Demethylating Agents.氮杂核苷类似物作为DNA去甲基化剂的治疗应用
Epigenomes. 2023 Jul 5;7(3):12. doi: 10.3390/epigenomes7030012.
4
Classification of Acute Myeloid Leukemia by Cell-Free DNA 5-Hydroxymethylcytosine.基于游离 DNA 5-羟甲基胞嘧啶的急性髓系白血病分类。
Genes (Basel). 2023 May 28;14(6):1180. doi: 10.3390/genes14061180.
5
Cellular Composition and 5hmC Signature Predict the Treatment Response of AML Patients to Azacitidine Combined with Chemotherapy.细胞组成和 5hmC 特征可预测 AML 患者接受阿扎胞苷联合化疗的治疗反应。
Adv Sci (Weinh). 2023 Aug;10(23):e2300445. doi: 10.1002/advs.202300445. Epub 2023 Jun 4.
6
Loss of MBD2 attenuates MLL-AF9-driven leukemogenesis by suppressing the leukemic cell cycle via CDKN1C.MBD2的缺失通过CDKN1C抑制白血病细胞周期，从而减弱MLL-AF9驱动的白血病发生。
Oncogenesis. 2021 Nov 17;10(11):79. doi: 10.1038/s41389-021-00366-3.
7
Low Plasma Citrate Levels and Specific Transcriptional Signatures Associated with Quiescence of CD34 Progenitors Predict Azacitidine Therapy Failure in MDS/AML Patients.低血浆柠檬酸盐水平及与CD34祖细胞静止相关的特定转录特征预示骨髓增生异常综合征/急性髓系白血病患者阿扎胞苷治疗失败
Cancers (Basel). 2021 Apr 30;13(9):2161. doi: 10.3390/cancers13092161.
8
Epigenetics in a Spectrum of Myeloid Diseases and Its Exploitation for Therapy.表观遗传学在一系列髓系疾病中的作用及其在治疗中的应用
Cancers (Basel). 2021 Apr 6;13(7):1746. doi: 10.3390/cancers13071746.
9
Epigenetic modifiers in normal and aberrent erythropoeisis.正常和异常红细胞生成中的表观遗传修饰物。
Semin Hematol. 2021 Jan;58(1):15-26. doi: 10.1053/j.seminhematol.2020.12.005. Epub 2020 Dec 29.
10
Acute Myeloid Leukemia: From Biology to Clinical Practices Through Development and Pre-Clinical Therapeutics.急性髓系白血病：从生物学通过研发和临床前治疗到临床实践
Front Oncol. 2020 Dec 9;10:599933. doi: 10.3389/fonc.2020.599933. eCollection 2020.
本文引用的文献
1
Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells.BET 蛋白抑制剂与 BCL2 或 MCL1 抑制剂联合治疗对 AML 原始细胞的疗效优于单一用药。
Blood Cancer J. 2019 Jan 15;9(2):4. doi: 10.1038/s41408-018-0165-5.
2
Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients.强化化疗后阿扎胞苷维持治疗可改善老年 AML 患者的DFS。
Blood. 2019 Mar 28;133(13):1457-1464. doi: 10.1182/blood-2018-10-879866. Epub 2019 Jan 10.
3
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.维奈托克联合地西他滨或阿扎胞苷治疗初治老年急性髓系白血病患者。
Blood. 2019 Jan 3;133(1):7-17. doi: 10.1182/blood-2018-08-868752. Epub 2018 Oct 25.
4
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.ivosidenib 治疗 IDH1 突变复发性或难治性 AML 的持久缓解。
N Engl J Med. 2018 Jun 21;378(25):2386-2398. doi: 10.1056/NEJMoa1716984. Epub 2018 Jun 2.
5
The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia.DOT1L 抑制剂 pinometostat 可降低 H3K79 甲基化水平，并在成人急性白血病中有一定的临床活性。
Blood. 2018 Jun 14;131(24):2661-2669. doi: 10.1182/blood-2017-12-818948. Epub 2018 May 3.
6
Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia.在复发性或难治性急性髓系白血病中，吉西他滨的剂量、方案、安全性和疗效。
Cancer. 2018 Jan 15;124(2):325-334. doi: 10.1002/cncr.31138. Epub 2017 Dec 6.
7
Dual inhibition of EZH1/2 breaks the quiescence of leukemia stem cells in acute myeloid leukemia.双重抑制 EZH1/2 可打破急性髓系白血病中白血病干细胞的静止状态。
Leukemia. 2018 Apr;32(4):855-864. doi: 10.1038/leu.2017.300. Epub 2017 Sep 27.
8
Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial.吉地他滨（SGI-110）用于初治急性髓系白血病患者：一项多中心、随机、1/2期试验的2期结果
Lancet Oncol. 2017 Oct;18(10):1317-1326. doi: 10.1016/S1470-2045(17)30576-4. Epub 2017 Aug 24.
9
Outcome of Azacitidine Therapy in Acute Myeloid Leukemia Is not Improved by Concurrent Vorinostat Therapy but Is Predicted by a Diagnostic Molecular Signature.阿扎胞苷治疗急性髓系白血病的疗效不受同时给予伏立诺他治疗的影响，但可由诊断性分子特征预测。
Clin Cancer Res. 2017 Nov 1;23(21):6430-6440. doi: 10.1158/1078-0432.CCR-17-1423. Epub 2017 Aug 1.
10
DNMT and HDAC inhibitors induce cryptic transcription start sites encoded in long terminal repeats.DNA甲基转移酶（DNMT）和组蛋白去乙酰化酶（HDAC）抑制剂可诱导长末端重复序列中编码的隐蔽转录起始位点。
Nat Genet. 2017 Jul;49(7):1052-1060. doi: 10.1038/ng.3889. Epub 2017 Jun 12.
Zotero 插件